FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsBabikian Healthcare Products CJSC
FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsCelmade
FDA warned Celmade over websites selling unapproved, misbranded injectable botulinum toxin products to U.S. consumers.
High risk -
DrugsVeganicSKN Limited
FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.
High risk -
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
DrugsKellin Chemicals Co., Ltd. - Zhangjiagang
Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
Drugskdc/one Chatsworth, Inc.
FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.
High risk -
DrugsBausch & Lomb Inc.
FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
High risk -
DrugsHappy Farm Botanicals, Inc.
Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.
High risk -
DrugsPeak Performance Peptides
Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.
High risk -
DrugsRoyal Peptides LLC
FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.
High risk -
DrugsNuScience Peptides LLC
FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.
High risk -
DrugsPeptide Partners LLC
Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.
High risk -
DrugsTXP Innovations LLC dba Tex Peptides
FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.
High risk -
DrugsReliance Life Sciences Private Limited
FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.
High risk -
DrugsShoolin Pharma Chem LLP
Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
High risk -
DrugsPReye, LLC
FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.
High risk -
DrugsSuretec Innovations, LLC
Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.
High risk -
DrugsEugia Pharma Specialities Limited
FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsFairyGene, Inc.
FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DrugsMaria E. De La Torre Silva, M.D.
Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.
Medium -
DrugsThomas Brunner Hygiene GmbH
Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.
High risk -
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsAlmon Healthcare Private Limited
Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
High risk -
DrugsBioMylz Pvt. Ltd.
FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
DrugsPratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.
FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsKetacyn Pharmaceuticals / www.ketacynpharma.com
FDA told Ketacyn Pharmaceuticals to stop selling unapproved ketamine injection and ketamine gummies to U.S. consumers online.
High risk -
DrugsExtra Medication / www.extramedication.com
FDA warned website Extra Medication for selling unapproved, misbranded ketamine drugs to U.S. consumers without prescriptions.
High risk -
DrugsPure Arylcyclohexylamine Store / www.arylcyclohexylamine.com
FDA warned Pure Arylcyclohexylamine Store it sells unapproved, misbranded ketamine drugs, including an injectable, to U.S. consumers online.
High risk -
DrugsAll Ketamine HCL / www.allketaminehcl.com
FDA warned website All Ketamine HCL for selling unapproved, misbranded ketamine drugs online without prescriptions.
High risk -
DrugsKetamine Troche Store / www.ketaminetrochestore.com
FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.
High risk -
DrugsBuy Keta Online / www.buyketaonline.com
FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.
High risk